Curadigm
Curadigm is an early-stage company focused on shifting the paradigm of therapeutic clearance, bioavailability, and efficacy to improve treatment outcomes for millions of patients. Curadigm was spun-off from Nanobiotix, a late-stage clinical company, in 2019 and maintains their commitment to cutting-edge therapeutic approaches. Curadigm has developed an industry-first nanotechnology designed to increase bioavailability and efficacy, while reducing off-target effects. Our product is administered intravenously just before the drug and “primes” the body to receive treatment by reducing rapid therapeutic clearance and hepatic toxicity. Curadigm’s priming technology is flexible and can be adapted to work with multiple therapeutic classes, including nanomedicines, nucleic acid therapeutics, small molecules, and gene editing technologies.
Company details
Find locations served, office locations
- Business Type:
- Technology
- Industry Type:
- Clinical Services
- Market Focus:
- Internationally (various countries)
About Us
Curadigm has ongoing programs and collaborations across many therapeutic classes, disease indications, and target tissues to improve bioavailability and efficacy. The company is also actively pursuing a therapeutic “rescue” pipeline to redefine the therapeutic profile of compounds that have failed in late stage clinical trials due to lack of efficacy or hepatic toxicity.
Importantly, our technology does not require modifying the therapeutic in any way, which could compromise its efficacy. Our approach allows us to redefine systemic bioavailability, enabling therapeutics hindered by poor bioavailability and low accumulation in target tissues, to become successful, driving the development of treatments to benefit patients that need them most.
The Nanoprimer is designed to impact only the cells involved in therapeutic clearance while leaving other liver functions undisturbed. This is accomplished by our precisely engineered lipid-based nanoparticle with specific physio-chemical properties that allow it to occupy Kupffer cells and liver sinusoidal endothelial cells (LSEC) that are involved in the clearance of most intravenous therapeutics. The Nanoprimer features simultaneously prevent it from accessing other liver-cell types, such as hepatocytes, that perform critical functions such as metabolization and detoxification.
